Drug Profile
Research programme: LRRK2 inhibitors - Charles River Laboratories
Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Charles River Laboratories
- Class Small molecules
- Mechanism of Action LRRK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for research development in Parkinson's-disease in USA
- 08 Dec 2015 Early research in Parkinson's disease in USA (unspecified route)